Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy

PLoS Computational Biology

Volumn 8, Issue 2, 2012, Pages

  Hosseini, Iraj ^a   Mac Gabhann, Feilim ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DISEASES; ENZYME ACTIVITY; SENSITIVITY ANALYSIS; T-CELLS; VIRUSES;

CELLULARS; COMPUTATIONAL SYSTEM; CYTIDINE; HIV INFECTION; IN-VITRO; MODELING PARAMETERS; MULTI-SCALES; MULTISCALE MODELING; REVERSE TRANSCRIPTION; SINGLE CELLS;

ORDINARY DIFFERENTIAL EQUATIONS;

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIF PROTEIN; VIRUS PROTEIN; ANTIRETROVIRUS AGENT; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE;

ARTICLE; BINDING SITE; CELL POPULATION; CONTROLLED STUDY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INTRACELLULAR SPACE; LYMPHOCYTE CULTURE; MATHEMATICAL MODEL; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; SENSITIVITY ANALYSIS; T LYMPHOCYTE; UPREGULATION; VIRION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; VIRUS RELEASE; VIRUS REPLICATION; BIOLOGICAL MODEL; BIOLOGY; CLUSTER ANALYSIS; COMPUTER SIMULATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MUTATION; PHYSIOLOGY; REPRODUCIBILITY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-RETROVIRAL AGENTS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CYTIDINE DEAMINASE; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; MUTATION; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS REPLICATION;

EID: 84861151989     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002371     Document Type: Article

References (90)

1. Chiu YL, Greene WC, (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26: 317-353.
2. Malim MH, (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364: 675-687.
3. Goila-Gaur R, Strebel K, (2008) HIV-1 Vif, APOBEC, and Intrinsic Immunity. Retrovirology 5: 51.
4. Albin JS, Harris RS, (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 12: e4.
5. Strebel K, Luban J, Jeang K-T, (2009) Human cellular restriction factors that target HIV-1 replication. BMC Med 7: 48.
6. Hultquist JF, Harris RS, (2009) Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol 4: 605.
7. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA Deamination Mediates Innate Immunity to Retroviral Infection. Cell 113: 803-809.
8. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
9. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
10. Lecossier D, Bouchonnet F, Clavel F, Hance AJ, (2003) Hypermutation of HIV-1 DNA in the Absence of the Vif Protein. Science 300: 1112.
11. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
12. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, et al. (2003) Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif. Cell 114: 21-31.
13. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucl Acids Res 32: 2421-2429.
14. Harris RS, Sheehy AM, Craig HM, Malim MH, Neuberger MS, (2003) DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol 4: 641-643.
15. Yang B, Chen K, Zhang C, Huang S, Zhang H, (2007) Virion-associated Uracil DNA Glycosylase-2 and Apurinic/Apyrimidinic Endonuclease Are Involved in the Degradation of APOBEC3G-edited Nascent HIV-1 DNA. J Biol Chem 282: 11667-11675.
16. Schumacher AJ, Hache G, MacDuff DA, Brown WL, Harris RS, (2008) The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction. J Virol 82: 2652-2660.
17. Kaiser SM, Emerman M, (2006) Uracil DNA Glycosylase Is Dispensable for Human Immunodeficiency Virus Type 1 Replication and Does Not Contribute to the Antiviral Effects of the Cytidine Deaminase Apobec3G. J Virol 80: 875-882.
18. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007) HIV-1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration. J Virol 81: 7099-7110.
19. Newman ENC, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity. Curr Biol 15: 166-170.
20. Bishop KN, Holmes RK, Malim MH, (2006) Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination. J Virol 80: 8450-8458.
21. Li X-Y, Guo F, Zhang L, Kleiman L, Cen S, (2007) APOBEC3G Inhibits DNA Strand Transfer during HIV-1 Reverse Transcription. J Biol Chem 282: 32065-32074.
22. Bishop KN, Verma M, Kim E-Y, Wolinsky SM, Malim MH, (2008) APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts. PLoS Pathog 4: e1000231.
23. Iwatani Y, Chan DSB, Wang F, Maynard KS, Sugiura W, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35: 7096-7108.
24. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L, (2006) Inhibition of Formula-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 Replication. J Virol 80: 11710-11722.
25. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, et al. (2007) The interaction of APOBEC3G with HIV-1 nucleocapsid inhibits tRNALys3 annealing to viral RNA. J Virol 81: 11322-11331.
26. Luo K, Wang T, Liu B, Tian C, Xiao Z, et al. (2007) Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation. J Virol 81: 7238-7248.
27. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, et al. (2007) Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1. J Virol 81: 13346-13353.
28. Browne EP, Allers C, Landau NR, (2009) Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387: 313-321.
29. Schumacher AJ, Nissley DV, Harris RS, (2005) APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci USA 102: 9854-9859.
30. von Schwedler U, Song J, Aiken C, Trono D, (1993) Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 67: 4945-4955.
31. Sova P, Volsky DJ, (1993) Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol 67: 6322-6326.
32. Simon J, Malim M, (1996) The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol 70: 5297-5305.
33. Chiu Y-L, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, et al. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435: 108-114.
34. Santoni de Sio FR, Trono D, (2009) APOBEC3G-Depleted Resting CD4+ T Cells Remain Refractory to HIV1 Infection. PLoS One 4: e6571.
35. Kamata M, Nagaoka Y, Chen ISY, (2009) Reassessing the Role of APOBEC3G in Human Immunodeficiency Virus Type 1 Infection of Quiescent CD4+ T-Cells. PLoS Pathog 5: e1000342.
36. Gramberg T, Sunseri N, Landau N, (2009) Accessories to the crime: Recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep 6: 36-42.
37. Malim MH, Emerman M, (2008) HIV-1 Accessory Proteins-Ensuring Viral Survival in a Hostile Environment. Cell Host Microbe 3: 388-398.
38. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
39. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, et al. (2004) Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway. J Biol Chem 279: 7792-7798.
40. Marin M, Rose KM, Kozak SL, Kabat D, (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
41. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability. Mol Cell 12: 591-601.
42. Wang Y, Shao Q, Yu X, Kong W, Hildreth JEK, et al. (2011) N-Terminal Hemagglutinin Tag Renders Lysine-Deficient APOBEC3G Resistant to HIV-1 Vif-Induced Degradation by Reduced Polyubiquitination. J Virol 85: 4510-4519.
43. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, et al. (2003) The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity. J Virol 77: 11398-11407.
44. Schröfelbauer B, Chen D, Landau NR, (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 101: 3927-3932.
45. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR, (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 101: 3770-3774.
46. Huthoff H, Malim MH, (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol 81: 3807-3815.
47. Zhang K-L, Mangeat B, Ortiz M, Zoete V, Trono D, et al. (2007) Model Structure of Human APOBEC3G. PLoS One 2: e378.
48. Khan M, Goila-Gaur R, Kao S, Miyagi E, Walker R, et al. (2009) Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology 6: 99.
49. Nowak MA, May R, (2001) Virus dynamics: Mathematical principles of immunology and virology New York Oxford University Press.
50. Wodarz D, Nowak MA, (2002) Mathematical models of HIV pathogenesis and treatment. BioEssays 24: 1178-1187.
51. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF, (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 105: 4832-4837.
52. Perelson AS, (2002) Modelling viral and immune system dynamics. Nat Rev Immunol 2: 28-36.
53. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time. Science 271: 1582-1586.
54. Strain MC, Richman DD, Wong JK, Levine H, (2002) Spatiotemporal Dynamics of HIV Propagation. J Theor Biol 218: 85-96.
55. Sedaghat AR, Siliciano RF, Wilke CO, (2009) Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 14: 263-271.
56. Speirs C, van Nimwegen E, Bolton D, Zavolan M, Duvall M, et al. (2005) Analysis of Human Immunodeficiency Virus Cytopathicity by Using a New Method for Quantitating Viral Dynamics in Cell Culture. J Virol 79: 4025-4032.
57. Reddy B, Yin J, (1999) Quantitative intracellular kinetics of HIV type 1. AIDS Res Hum Retroviruses 15: 273-283.
58. Zarrabi N, Mancini E, Tay J, Shahand S, Sloot PMA, (2010) Modeling HIV-1 intracellular replication: two simulation approaches. Procedia Comput Sci 1: 555-564.
59. Haseltine EL, Rawlings JB, Yin J, (2005) Dynamics of viral infections: incorporating both the intracellular and extracellular levels. Comput Chem Eng 29: 675-686.
60. Benedict K, Mac Gabhann F, Amanfu R, Chavali A, Gianchandani E, et al. (2011) Systems Analysis of Small Signaling Modules Relevant to Eight Human Diseases. Ann Biomed Eng 39: 621-635.
61. Arnold E, Sarafianos SG, (2008) Molecular biology: An HIV secret uncovered. Nature 453: 169-170.
62. Arhel N, (2010) Revisiting HIV-1 uncoating. Retrovirology 7: 96.
63. Marodon G, Warren D, Filomio MC, Posnett DN, (1999) Productive infection of double-negative T cells with HIV in vivo. Proc Natl Acad Sci USA 96: 11958-11963.
64. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, et al. (2008) HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372: 136-146.
65. Dang Y, Siew LM, Zheng Y-H, (2008) APOBEC3G Is Degraded by the Proteasomal Pathway in a Vif-dependent Manner without Being Polyubiquitylated. J Biol Chem 283: 13124-13131.
66. Auclair J, Somasundaran M, Schiffer C, (2005) Low Resolution Structural Mapping of HIV-1 Vif and its Interaction with APOBEC3G. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment.
67. Xu H, Chertova E, Chen J, Ott DE, Roser JD, et al. (2007) Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360: 247-256.
68. van 't Wout AB, Lehrman GK, Mikheeva SA, O'Keeffe GC, Katze MG, et al. (2003) Cellular Gene Expression upon Human Immunodeficiency Virus Type 1 Infection of CD4+-T-Cell Lines. J Virol 77: 1392-1402.
69. Kim SY, Byrn R, Groopman J, Baltimore D, (1989) Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 63: 3708-3713.
70. Schupbach J, (2002) Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Rev 4: 83-92.
71. Chono H, Matsumoto K, Tsuda H, Saito N, Lee K, et al. (2011) Acquisition of HIV-1 Resistance in T Lymphocytes Using an ACA-Specific E. coli mRNA Interferase. Hum Gene Ther 22: 35-43.
72. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E, (1991) Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 65: 6811-6816.
73. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, et al. (1993) Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 67: 2182-2190.
74. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, et al. (2001) HIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid Tissues. Immunity 15: 671-682.
75. Chun T-W, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
76. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, et al. (1996) Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue. Science 274: 985-989.
77. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, et al. (1999) Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 189: 1545-1554.
78. Chen HY, Di Mascio M, Perelson AS, Ho DD, Zhang L, (2007) Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci USA 104: 19079-19084.
79. Reilly C, Wietgrefe S, Sedgewick G, Haase A, (2007) Determination of simian immunodeficiency virus production by infected activated and resting cells. AIDS 21: 163-168.
80. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354: 1782-1785.
81. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
82. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
83. Cen S, Peng Z-G, Li X-Y, Li Z-R, Ma J, et al. (2010) Small Molecular Compounds Inhibit HIV-1 Replication through Specifically Stabilizing APOBEC3G. J Biol Chem 285: 16546-16552.
84. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, et al. (2008) Small-molecule inhibition of HIV-1 Vif. Nat Biotech 26: 1187-1192.
85. Jeffrey Fessel W, (2005) A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem. Med Hypotheses 64: 261-263.
86. Stopak KS, Chiu Y-L, Kropp J, Grant RM, Greene WC, (2007) Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells. J Biol Chem 282: 3539-3546.
87. Farrow MA, Kim E-Y, Wolinsky SM, Sheehy AM, (2011) NFAT and IRF Proteins Regulate Transcription of the Anti-HIV Gene, APOBEC3G. J Biol Chem 286: 2567-2577.
88. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, et al. (2007) Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 81: 8236-8246.
89. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK, (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol 83: 1992-2003.
90. Mangeat B, Turelli P, Liao S, Trono D, (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279: 14481-14483.